| Detailed information |
|---|
| CancerLivER ID | 2526 |
| Biomarker | Plasminogen, Corticotropin releasing hormone bindingprotein, GRO2 oncogene, Interferon gamma-inducible protein 10, alpha-Platelet-derived growth factor receptor precursor, Cell division cycle 25C, Cytochrome P450-IIC, Human intercrine-a(hIRH), IL-8 |
| Biomarker Name/Symbol (given in Publication) | Plasminogen, Corticotropin releasing hormone-binding protein, GRO2 oncogene, Interferon gamma-inducible protein 10, alpha-Platelet-derived growth factor receptor precursor, Cell division cycle 25C, Cytochrome P450-IIC, Human intercrine-a(hIRH), IL-8 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential diagnostic marker for HCC and downregulated in HCC than non-tumorous tissue ( with average ratio more than 2) ; but not validated on independent dataset |
| Experimental Condition | HCC v/s non-tumor |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in HCC than non-tumorous tissue ( with average ratio more than 2) |
| Level of significance | NA |
| Source | Tissue |
| PMID | 11283847 |
| Type of Biomarker | Diagnostic |
| Pathway | NA |
| Cohort | Paired HCC and non-tumorous tissues from 10 HCC patients |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCC v/s non-tumor |
| Year of Publication | 2001 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |